Evidence mapPaperPMID 39137120Full record

ArticleDiabetes2024

PAK3 Exacerbates Cardiac Lipotoxicity via SREBP1c in Obesity Cardiomyopathy.

Xinyi Chen, Andrea Ruiz-Velasco, Zhiyong Zou, Susanne S Hille, Claire Ross, Oveena Fonseka, Sanskruti R Gare, Nasser Hawimel O Alatawi, Rida Raja, Jiayan Zhang and 13 more

Abstract read
In one paragraph

Article in Diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Xinyi ChenFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Andrea Ruiz-VelascoFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Zhiyong ZouFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Susanne S HilleDepartment of Internal Medicine III, University of Kiel, Kiel, Germany.
Claire RossFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Oveena FonsekaFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Sanskruti R GareFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Nasser Hawimel O AlatawiFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Rida RajaFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Jiayan ZhangFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Namrita KaurFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Xiangjun ZhaoFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Henrietta Morrell-DaviesFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Jessica M MillerSurgery Department, Baylor College of Medicine, Houston, TX.
Riham R E AbouleisaSurgery Department, Baylor College of Medicine, Houston, TX.
Qinghui OuInstitute of Molecular Cardiology, University of Louisville, Louisville, KY.
Derk FrankDepartment of Internal Medicine III, University of Kiel, Kiel, Germany.
Martin K RutterFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Christian PinaliFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Tao WangFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Tamer M A MohamedFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.
Oliver J MüllerDepartment of Internal Medicine III, University of Kiel, Kiel, Germany.
Wei LiuFaculty of Biology, Medicine and Health, The University of Manchester, Manchester, U.K.ORCID 0009-0005-4978-6029

Funding

Induction of Cardiomyocyte Proliferation via Transient Expression of Cell Cycle Factors as a Promising Therapy for Heart FailureR01HL147921 · BAYLOR COLLEGE OF MEDICINE · 2025 to 2025
$750k
Defining the major signaling mechanism which controls spontaneous cardiomyocyte proliferation in the Neonatal StageR01HL178610 · BAYLOR COLLEGE OF MEDICINE · 2025 to 2025
$747k
Deciphering the Relationship Between Cardiomyocyte Metabolic Configuration and Cell Cycle Re-entryF32HL149140 · NHLBI · UNIVERSITY OF LOUISVILLE · PI Riham Raafat Elgharib Abouleisa · 2023 to 2023
$83k
British Heart Foundation FS/15/16/31477British Heart Foundation FS/18/73/33973British Heart Foundation FS/PHD/22/29307British Heart Foundation PG/19/66/34600British Heart Foundation PG/22/10904British Heart Foundation PG/22/11075NHLBI NIH HHS F32 HL149140NHLBI NIH HHS R01 HL147921NHLBI NIH HHS R01 HL178610NIGMS NIH HHS P30 GM127607
6 · The paper itself

Abstract

Obesity-induced lipid overload in cardiomyocytes contributes to profound oxidative stress and cardiomyopathy, culminating in heart failure. In this study, we investigate a novel mechanism whereby lipids accumulate in cardiomyocytes, and seek the relevant treatment strategies. P21-activated kinase 3 (PAK3) was elevated in obese human myocardium, and the murine hearts and cardiomyocytes upon diet- or fatty acid-induced stress, respectively. Mice with cardiac-specific overexpression of PAK3 were more susceptible to the development of cardiac dysfunction upon diet stress, at least partially, because of increased deposition of toxic lipids within the myocardium. Mechanistically, PAK3 promoted the nuclear expression of sterol regulatory element binding protein 1c (SREBP1c) through activation of mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase β-1 (S6K1) pathway in cardiomyocytes, resulting in abnormal lipid genes profile, accumulation of excessive lipids, and oxidative stress. More importantly, PAK3 knockdown attenuated fatty acid-induced lipotoxicity and cell death in rat and human cardiomyocytes. More importantly, the S6K1 or SREBP1c inhibitor alleviated PAK3-triggered intracellular lipid overload and cardiac dysfunction under obese stress. Collectively, we have demonstrated that PAK3 impairs myocardial lipid homeostasis, while inhibition of cardiac lipotoxicity mitigates cardiac dysfunction. Our study provides a promising therapeutic strategy for ameliorating obesity cardiomyopathy. ARTICLE HIGHLIGHTS:

Indexed as

CardiomyopathiesMyocytes, CardiacObesityp21-Activated KinasesSterol Regulatory Element Binding Protein 1AnimalsHumansLipid MetabolismMaleMiceMyocardiumOxidative StressRatsRibosomal Protein S6 Kinases, 90-kDaSignal TransductionTOR Serine-Threonine Kinasesp21-Activated KinasesRibosomal Protein S6 Kinases, 90-kDaRps6ka1 protein, mouseSterol Regulatory Element Binding Protein 1TOR Serine-Threonine Kinases

Identifiers

PMID39137120
PMCPMC11493761

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.